Upfront Ruxolitinib for Chronic Graft-vs-host Disease

NCT06695507 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Study closed due to slow enrollment.

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG: Ruxolitinib

Sponsor

Children's Hospital Medical Center, Cincinnati